DMC vs AVLN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
DMC · Del Monte$27.39 ▼ 0.87%
AVLN · Avalyn Pharma$29.15 ▲ 9.30%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- DMC -33.4%
- AVLN -1.2%
Head to head
| Metric | DMC | AVLN |
|---|---|---|
| Price | $27.39 | $29.15 |
| Change today | ▼ 0.87% | ▲ 9.30% |
| Market cap | $1.29B | $1.29B |
| Return, 3 months | -8.6% | -15.7% |
| Return, year to date | -21.1% | – |
| Return, 1 year | -24.0% | – |
| P/E (TTM) | 16.1 | -12.5 |
| P/B | 0.6 | 3.2 |
| P/E percentile vs own 5y | 67th | 89th |
| Dividend yield | 4.38% | – |
| Revenue growth (YoY, latest qtr) | +7.2% | – |
| Net profit growth (YoY) | +166.5% | -43.3% |
| Gross margin | 9.6% | – |
| Operating margin | 3.8% | – |
| Net margin | 1.9% | – |
| Return on equity | 4.0% | -25.9% |
| Analyst target vs. price | – | +93.2% |
| Analyst buy share | – | 100% |
| RSI (14) | 40 | 60 |
| 30-day volatility | 38.3% | 63.5% |
| Max drawdown, 1 year | -36.5% | -40.6% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AVLN is the largest of the group by market value.
- AVLN carries the lowest trailing P/E.
- DMC has been the calmest stock over the last 30 days.